
The Gambia ALMA Quarterly Report Quarter Four, 2022




Scorecard for Accountability and Action



Commodities Financed		
LLIN financing 2022 projection (% of need)		100
Public sector RDT financing 2022 projection (% of need)		100
Public sector ACT financing 2022 projection (% of need)		100
Policy		
Signed, ratified and deposited the AMA instrument at the AUC		
Malaria activities targeting refugees in Malaria Strategic Plan	I	
Malaria activities targeting IDPs in Malaria Strategic Plan	Ť	
Country Reporting Launch of Zero Malaria Starts with Me Campaign		
Resistance Monitoring, Implementation and Impact		
Drug Resistance Monitoring Conducted (2018-2020) and data reported to WHO		
Insecticide classes with mosquito resistance in representative sentinel sites confirmed since 2010		3
Insecticide resistance monitored since 2015 and data reported to WHO		r
National Insecticide Resistance Monitoring and Management Plan		
RDTs in stock (>6 months stock)		
ACTs in stock (>6 months stock)		
LLIN/IRS campaign on track		
Operational LLIN/IRS coverage (% of at risk population)		100
On track to reduce case incidence by ≥40% by 2021 (vs 2015)		
On track to reduce case mortality by ≥40% by 2021 (vs 2015)		
Tracer Indicators for Maternal and Child Health, NTDs ar	d C	ovid 19
Scale of Implementation of iCCM		
Mass Treatment Coverage for Neglected Tropical Disease (NTD index, %)(2021)	•	41
Estimated % of children (0–14 years old) living with HIV who have access to antiretroviral therapy (2021)		41
Vitamin A Coverage 2021 (2 doses)		27
DPT3 coverage 2021 (vaccination among 0-11 month olds)		82
% Population Fully Vaccinated Against COVID-19		17

The entire population of The Gambia is at high risk of malaria and transmission is intense for most of the year. The annual reported number of malaria cases in 2021 was 77,287 with 42 deaths.

Key



The Gambia ALMA Quarterly Report Quarter Four, 2022



Malaria

Global Fund Update

The Global Fund has announced that The Gambia will receive US\$40.97 million for HIV, tuberculosis, malaria, and health systems strengthening as the country allocation for 2024-2026. The Global Fund has determined the total allocation amount based on The Gambia's disease burden and income level, as well as several other factors. The malaria component is also allocated a specific proportion of the total, according to a formula developed by the Global Fund that takes into account several factors, including disease burden and the importance of sustaining life-saving essential services. For The Gambia this is calculated at US\$20.2 million. The allocations to the individual disease components are not fixed, and can be adjusted according to decisions made at country level. The Gambia is urged to ensure that resources are allocated to malaria control from the overall Global Fund country allocation, as well as from domestic resources, to accelerate progress.

Progress

The country continues to work on strengthening and maintaining health services following the devastating impact of the COVID-19 pandemic. In this regard, The Gambia secured sufficient resources to finance the malaria commodities required for 2022. The country has procured sufficient LLINs and carried out IRS to sustain 100% operational coverage of the targeted at risk population. The country has recently submitted the results of insecticide resistance monitoring to WHO and has carried out drug resistance testing since 2018 and has reported the results to WHO. The national strategic plan includes activities targeting refugees. The Gambia has decreased the estimated malaria incidence by more than 40% since 2015.

In line with the priority agenda of the ALMA chair, His Excellency President Umaro Sissoco Embaló, the Gambia has enhanced the tracking and accountability mechanisms for malaria with the development of a Malaria Control and Elimination Scorecard, although this has not yet been shared to the ALMA Scorecard Hub.

Impact

The annual reported number of malaria cases in 2021 was 77,287 with 42 deaths.

Key Challenge

 Sustaining the delivery of essential life-saving interventions during the COVID-19 pandemic including for Reproductive, Maternal, Newborn, Adolescent and Child health, malaria and Neglected Tropical Diseases. **Previous Key Recommended Actions**

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
Impact	Ensure that malaria services including case management and vector control are sustained and implemented whilst using COVID-19 sensitive guidelines during the pandemic	Q4 2022		The country has implemented the SMC campaign. Drug resistance testing is being implemented in 3 sites for antimalarial drugs. Routine interventions such as ITN distribution through the ANC and EPI services, diagnosis, treatment were implemented as planned. The country has sufficient stocks of ACT and RDTs
Policy	Sign, ratify and deposit the AMA instrument at the AUC	Q1 2023		Deliverable not yet due

RMNCAH and NTDs

Progress

Progress in addressing Neglected Tropical Diseases (NTDs) in The Gambia is measured using a composite index calculated from preventive chemotherapy coverage achieved for schistosomiasis, soil transmitted helminths and trachoma. In 2021, preventive chemotherapy coverage was 100% for trachoma and 47% for soil-transmitted helminths and 15% for schistosomiasis. The NTD preventive chemotherapy coverage index for Gambia in 2021 is 41, which represents a very substantial increase compared with the 2020 index value (1).

Previous Key Recommended Actions

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
RMNCAH1: Impact	Ensure that essential RMNCAH services are sustained and implemented whilst using Covid-19 sensitive guidelines during the pandemic. Address any stock-outs of essential RMNCAH commodities	Q4 2022		The Ministry of Health established a committee to oversee the implementation of activities to ensure continuity of Health Services in the country. RMNCAH routine activities continued as planned including the monitoring of Reproductive Health services in the health facilities, training of health care providers on Emergency Maternal, Neonatal and Child Health, monitoring on Kabulo bama implementation at community level which is a model of cluster supporting reproductive health at community level

¹ RMNCAH metrics, recommended actions and response tracked through WHO

Objective	Action Item	Suggested completion timeframe	Progress	Comments - key activities/accomplishments since last quarterly report
NTDs	Given the high coverage of Preventive Chemotherapy (PC) for trachoma, work to increase the preventive chemotherapy coverage for soil transmitted helminthiasis and implement preventive chemotherapy for schistosomiasis, including mobilizing the necessary resources and community surveillance systems. Ensure that NTD interventions including Mass Drug Administration, vector control and Morbidity Management and Disability Prevention are sustained and implemented whilst using Covid-19 sensitive guidelines during the pandemic. This includes prioritising key necessary catch-up activities	Q4 2022		The country is conducting the NTD control and elimination activities whilst respecting COVID-19 preventive measures. The country completed the NTD Master plan for 2022-2026 and is waiting for its validation. The country is also conducting NTD surveillance activities while waiting to have schistosomiasis and soil transmitted helminthiasis MDA medicines expected in the first quarter of 2023. MDA will be conducted once those medicines are received.

The Gambia has responded positively to the RMNCAH recommended action addressing the low coverage of vitamin A and continues to track progress as actions are implemented.

